Indian Journal of Urology Users online:1640  
IJU
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size
CASE REPORT
Year : 2017  |  Volume : 33  |  Issue : 1  |  Page : 76-78

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma


1 The Gastrointestinal Unit, The Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK
2 Department of Urology, Frimley Health NHS Foundation Trust, Frimley, Surrey, GU16 7UJ, UK
3 Targeted Cancer Therapy, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, GU2 7WG, UK

Correspondence Address:
Hardev S Pandha
Targeted Cancer Therapy, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, GU2 7WG
UK
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0970-1591.194787

Rights and Permissions

Tyrosine kinase inhibitors sunitinib and pazopanib are used as first-line agents in the treatment of metastatic renal cell carcinoma. Treatment-related toxicities have been described with both these drugs. This report describes a patient with metastatic renal carcinoma who developed trismus while being treated with these agents and is, to the best of our knowledge, the first such case to be reported.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed580    
    Printed12    
    Emailed0    
    PDF Downloaded15    
    Comments [Add]    

Recommend this journal

 

HEALTHWARE INDIA